Green Thumb Industries Reports First Quarter 2026 Results

• Event: Q1 2026 Earnings Release (May 6, 2026).
• Revenue: $300.2 million, up 7.4% year-over-year (YoY). Retail revenue up 4.7% YoY.
• Profitability: Net income of $15.4 million ($0.07/share) vs $8.3 million prior year. Normalized EBITDA $93.5 million (31.2% margin). Gross profit margin declined to 47.9% from 51.3% YoY.
• Cash & Liquidity: Cash position at $344.5 million. Operating cash flow $76.0 million.
• Capital Allocation: Aggressive share repurchases totaling ~$77.7 million YTD 2026 (~13.4 million shares). Total program authorization increased to $150 million in April 2026.
• Debt: Syndicated credit facility increased by $50 million (total outstanding debt $289.9 million, including $188.8 million senior debt).
• Operations: Conditionally awarded Texas Compassionate Use Program license. Submitted DEA registration applications following federal rescheduling of medical cannabis to Schedule III.

• Positive Confirmation: The earnings report validates the financial stability required to execute the strategic pivot announced on May 4, 2026 (DEA Registration/Schedule III). It confirms the company has sufficient cash flow ($76M operating) to fund operations and buybacks without immediate distress.
• Margin Pressure: Gross margin compression (51.3% to 47.9%) indicates pricing pressure or cost inflation, which is a negative signal despite revenue growth. This suggests volume growth may be offset by lower per-unit profitability.
• One-Time Income: The significant jump in Net Income ($8.3M to $15.4M) is partially driven by one-time arbitration settlement and related party investment income. Normalized EBITDA growth is more modest (from ~$85M implied Q1 2025 to $93.5M).
• Regulatory Execution: The conditional Texas license adds a new market footprint, but "conditional" status implies regulatory hurdles remain before revenue contribution.
• Verdict: This news is Routine - Positive. It confirms the thesis established by the May 4th DEA filing announcement rather than introducing a new, unexpected catalyst. The financials are solid but show underlying margin headwinds that temper enthusiasm.

• Overview: Green Thumb Industries (GTII) is a national cannabis consumer packaged goods company and retailer operating in 14 U.S. markets with approximately 113 retail locations (RISE Dispensaries).
• Flagship Project/Brand Portfolio: The company owns and operates RISE Dispensaries and manages a portfolio of brands including RYTHM, incredibles, Dogwalkers, Beboe, &Shine, Doctor Solomon’s, and Good Green.
• Development: The company is transitioning from a purely state-regulated model to one aligned with federal rescheduling (Schedule III), aiming to normalize operations and reduce tax burdens via Section 280E relief. Expansion into Texas represents the next major geographic growth initiative.